1. Home
  2. SXT vs ACAD Comparison

SXT vs ACAD Comparison

Compare SXT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SXT
  • ACAD
  • Stock Information
  • Founded
  • SXT 1882
  • ACAD 1993
  • Country
  • SXT United States
  • ACAD United States
  • Employees
  • SXT N/A
  • ACAD N/A
  • Industry
  • SXT Major Chemicals
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • SXT Industrials
  • ACAD Health Care
  • Exchange
  • SXT Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • SXT 4.5B
  • ACAD 4.3B
  • IPO Year
  • SXT N/A
  • ACAD 2004
  • Fundamental
  • Price
  • SXT $103.02
  • ACAD $24.41
  • Analyst Decision
  • SXT Buy
  • ACAD Buy
  • Analyst Count
  • SXT 2
  • ACAD 21
  • Target Price
  • SXT $110.00
  • ACAD $29.30
  • AVG Volume (30 Days)
  • SXT 528.9K
  • ACAD 1.9M
  • Earning Date
  • SXT 10-31-2025
  • ACAD 11-05-2025
  • Dividend Yield
  • SXT 1.63%
  • ACAD N/A
  • EPS Growth
  • SXT 53.07
  • ACAD 615.00
  • EPS
  • SXT 3.17
  • ACAD 1.33
  • Revenue
  • SXT $1,575,588,000.00
  • ACAD $1,018,885,000.00
  • Revenue This Year
  • SXT $4.42
  • ACAD $14.01
  • Revenue Next Year
  • SXT $5.78
  • ACAD $11.72
  • P/E Ratio
  • SXT $31.83
  • ACAD $18.30
  • Revenue Growth
  • SXT 4.95
  • ACAD 14.41
  • 52 Week Low
  • SXT $66.15
  • ACAD $13.40
  • 52 Week High
  • SXT $121.54
  • ACAD $26.65
  • Technical
  • Relative Strength Index (RSI)
  • SXT 33.87
  • ACAD 48.67
  • Support Level
  • SXT $100.03
  • ACAD $23.34
  • Resistance Level
  • SXT $114.33
  • ACAD $24.93
  • Average True Range (ATR)
  • SXT 3.45
  • ACAD 0.81
  • MACD
  • SXT -1.32
  • ACAD -0.20
  • Stochastic Oscillator
  • SXT 33.47
  • ACAD 35.28

About SXT Sensient Technologies Corporation

Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are; Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: